🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for CAR T Cell Therapy

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites📍 Gilbert📍 Scottsdale📍 Scottsdale Lyell Immunopharma, Inc. · Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma NCT05948033Phase 1, Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: CD70-targeting CAR-T cells BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site📍 Beijing Peking University People's Hospital · Tests: BCMA-CD19 CAR-T therapy To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma NCT07179484n/a1 site📍 Beijing Beijing GoBroad Hospital · Tests: CT041 autologous CAR T-cell injection CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD19x22 CAR T CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy. NCT06733610Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: universal allogeneic anti-CD19/BCMA CAR T-cells Universal CAR-T Cell Therapy for MM NCT07248176NA1 site📍 Shanghai Bioray Laboratories · Tests: Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites📍 Beijing📍 Beijing📍 Chongqing Chongqing Precision Biotech Co., Ltd · Tests: pCAR-19B cells A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases NCT06980597Phase 12 sites📍 Beijing📍 Beijing Beijing GoBroad Hospital · Tests: OL-108 CD19 CAR-T Therapy for Refractory Childhood-Onset Systemic Lupus Erythematosus NCT07855302Phase 11 site📍 Seoul Seoul National University Hospital · Tests: SNUH-CD19-CAR-T Cells, Lymphodepleting Chemotherapy A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors NCT07250386Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CEA-targeted CAR-T (Intravenous), CEA-targeted CAR-T (Intrapleural) CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases NCT06941129Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: UCAR T-cell Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease NCT07129642EARLY Phase 11 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Allogeneic CAR-T A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors NCT06717022NA1 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: CHT102 allogeneic CAR T cells Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma NCT07200102Phase 11 site📍 St Louis Washington University School of Medicine · Tests: Selinexor GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer NCT07489287Phase 11 site📍 Buffalo Roswell Park Cancer Institute · Tests: GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site📍 Seattle University of Washington · Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Ther… A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia NCT06285825Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Emapalumab Nutrition OUtReach In Systems of Healthcare NCT06802406NA4 sites📍 Stanford📍 Fairway📍 New York University of Kansas Medical Center · Tests: Food Bags Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy NCT05757219Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma NCT07333430Phase 11 site📍 Jerusalem Hadassah Medical Organization · Tests: Naive HBI0101 CAR-T Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma NCT05312801Phase 12 sites📍 Cleveland📍 Cleveland Luminary Therapeutics · Tests: BAFF CAR-T Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis NCT06569472Phase 11 site📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CD19-targetd CAR-T Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0) NCT07472972n/a1 site📍 Zurich University of Zurich NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NCT07052305Phase 11 site📍 St Louis Washington University School of Medicine · Tests: NT-I7, CAR T-cell therapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site📍 Beijing Peking University People's Hospital · Tests: Senl_B19 autologous CAR-T (S1904) treatment THRIVE-CAR-T Digital App NCT06665295NA1 site📍 Boston Patrick C. Johnson, MD · Tests: THRIVE-CAR-T CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia NCT06696846Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CD70 CAR-NK A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Assessing DCog Short for Neurotoxicity in CAR-T NCT07403812NA1 site📍 Boston Beth Israel Deaconess Medical Center · Tests: DCog Short
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy